Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Francis Tally and the discovery and development of tigecycline: a personal reminiscence.

Projan SJ.

Clin Infect Dis. 2010 Jan 1;50 Suppl 1:S24-5. doi: 10.1086/647941.

PMID:
20067389
2.

Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.

Petersen PJ, Jones CH, Venkatesan AM, Mansour TS, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2009 Feb;53(2):370-84. doi: 10.1128/AAC.01047-08. Epub 2008 Nov 10.

3.

Whither antibacterial drug discovery?

Projan SJ.

Drug Discov Today. 2008 Apr;13(7-8):279-80. doi: 10.1016/j.drudis.2008.03.010. No abstract available.

PMID:
18405838
4.

Late stage antibacterial drugs in the clinical pipeline.

Projan SJ, Bradford PA.

Curr Opin Microbiol. 2007 Oct;10(5):441-6. Epub 2007 Oct 22. Review.

PMID:
17950658
5.

(Genome) size matters.

Projan SJ.

Antimicrob Agents Chemother. 2007 Apr;51(4):1133-4. Epub 2007 Feb 12. No abstract available.

6.

Transcriptional profiling of a Staphylococcus aureus clinical isolate and its isogenic agr and sarA mutants reveals global differences in comparison to the laboratory strain RN6390.

Cassat J, Dunman PM, Murphy E, Projan SJ, Beenken KE, Palm KJ, Yang SJ, Rice KC, Bayles KW, Smeltzer MS.

Microbiology. 2006 Oct;152(Pt 10):3075-90.

PMID:
17005987
7.

Characterization of the Staphylococcus aureus heat shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA turnover.

Anderson KL, Roberts C, Disz T, Vonstein V, Hwang K, Overbeek R, Olson PD, Projan SJ, Dunman PM.

J Bacteriol. 2006 Oct;188(19):6739-56.

8.

Staphylococcal vaccines and immunotherapy: to dream the impossible dream?

Projan SJ, Nesin M, Dunman PM.

Curr Opin Pharmacol. 2006 Oct;6(5):473-9. Epub 2006 Jul 25. Review.

PMID:
16870507
9.
10.

Characterizing the effect of the Staphylococcus aureus virulence factor regulator, SarA, on log-phase mRNA half-lives.

Roberts C, Anderson KL, Murphy E, Projan SJ, Mounts W, Hurlburt B, Smeltzer M, Overbeek R, Disz T, Dunman PM.

J Bacteriol. 2006 Apr;188(7):2593-603.

11.

Transcription Profiling of the mgrA Regulon in Staphylococcus aureus.

Luong TT, Dunman PM, Murphy E, Projan SJ, Lee CY.

J Bacteriol. 2006 Mar;188(5):1899-910.

12.

Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States.

Tenover FC, McDougal LK, Goering RV, Killgore G, Projan SJ, Patel JB, Dunman PM.

J Clin Microbiol. 2006 Jan;44(1):108-18.

13.

Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates.

McAleese F, Murphy E, Babinchak T, Singh G, Said-Salim B, Kreiswirth B, Dunman P, O'Connell J, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2005 Nov;49(11):4521-9.

14.

Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge.

Wu J, Kobayashi M, Sousa EA, Liu W, Cai J, Goldman SJ, Dorner AJ, Projan SJ, Kavuru MS, Qiu Y, Thomassen MJ.

Mol Cell Proteomics. 2005 Sep;4(9):1251-64. Epub 2005 Jun 12.

15.

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.

McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2005 May;49(5):1865-71.

16.

MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus.

Truong-Bolduc QC, Dunman PM, Strahilevitz J, Projan SJ, Hooper DC.

J Bacteriol. 2005 Apr;187(7):2395-405.

17.

Comparative genomics of Staphylococcus aureus musculoskeletal isolates.

Cassat JE, Dunman PM, McAleese F, Murphy E, Projan SJ, Smeltzer MS.

J Bacteriol. 2005 Jan;187(2):576-92.

18.

Effect of mild acid on gene expression in Staphylococcus aureus.

Weinrick B, Dunman PM, McAleese F, Murphy E, Projan SJ, Fang Y, Novick RP.

J Bacteriol. 2004 Dec;186(24):8407-23.

19.

Antibacterial drug discovery: is it all downhill from here?

Projan SJ, Shlaes DM.

Clin Microbiol Infect. 2004 Nov;10 Suppl 4:18-22. Review.

20.

Uses of Staphylococcus aureus GeneChips in genotyping and genetic composition analysis.

Dunman PM, Mounts W, McAleese F, Immermann F, Macapagal D, Marsilio E, McDougal L, Tenover FC, Bradford PA, Petersen PJ, Projan SJ, Murphy E.

J Clin Microbiol. 2004 Sep;42(9):4275-83.

21.

Small molecules for small minds? The case for biologic pharmaceuticals.

Projan SJ, Gill D, Lu Z, Herrmann SH.

Expert Opin Biol Ther. 2004 Aug;4(8):1345-50. Review.

PMID:
15268667
22.

Global gene expression in Staphylococcus aureus biofilms.

Beenken KE, Dunman PM, McAleese F, Macapagal D, Murphy E, Projan SJ, Blevins JS, Smeltzer MS.

J Bacteriol. 2004 Jul;186(14):4665-84.

23.

Hydrophobic acetal and ketal derivatives of mannopeptimycin-alpha and desmethylhexahydromannopeptimycin-alpha: semisynthetic glycopeptides with potent activity against Gram-positive bacteria.

Dushin RG, Wang TZ, Sum PE, He H, Sutherland AG, Ashcroft JS, Graziani EI, Koehn FE, Bradford PA, Petersen PJ, Wheless KL, How D, Torres N, Lenoy EB, Weiss WJ, Lang SA, Projan SJ, Shlaes DM, Mansour TS.

J Med Chem. 2004 Jul 1;47(14):3487-90.

PMID:
15214775
24.

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

Bauer G, Berens C, Projan SJ, Hillen W.

J Antimicrob Chemother. 2004 Apr;53(4):592-9. Epub 2004 Feb 25.

PMID:
14985271
25.

Effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection.

Weiss WJ, Lenoy E, Murphy T, Tardio L, Burgio P, Projan SJ, Schneewind O, Alksne L.

J Antimicrob Chemother. 2004 Mar;53(3):480-6. Epub 2004 Feb 4.

PMID:
14762051
26.

Why is big Pharma getting out of antibacterial drug discovery?

Projan SJ.

Curr Opin Microbiol. 2003 Oct;6(5):427-30. Review.

PMID:
14572532
27.

Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon.

Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ.

Microbiology. 2003 Oct;149(Pt 10):2719-32.

PMID:
14523105
28.

Recurrent episodes of shock-like syndrome caused by the same strain of vancomycin-resistant Enterococcus faecium in a pediatric patient.

Papp L, McNeeley DF, Projan SJ, Bradford PA, Frost A, Nesin M.

Microb Drug Resist. 2003 Fall;9(3):307-12.

PMID:
12959410
29.

Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus.

Ruzin A, Severin A, Moghazeh SL, Etienne J, Bradford PA, Projan SJ, Shlaes DM.

Biochim Biophys Acta. 2003 May 2;1621(2):117-21.

PMID:
12726988
30.

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA.

Antimicrob Agents Chemother. 2003 Mar;47(3):972-8.

31.

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.

Visalli MA, Murphy E, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2003 Feb;47(2):665-9.

32.

Global regulation of Staphylococcus aureus genes by Rot.

Saïd-Salim B, Dunman PM, McAleese FM, Macapagal D, Murphy E, McNamara PJ, Arvidson S, Foster TJ, Projan SJ, Kreiswirth BN.

J Bacteriol. 2003 Jan;185(2):610-9.

33.

Antimicrobials: new solutions badly needed.

Projan SJ, Youngman PJ.

Curr Opin Microbiol. 2002 Oct;5(5):463-5. No abstract available.

PMID:
12354551
34.

New (and not so new) antibacterial targets - from where and when will the novel drugs come?

Projan SJ.

Curr Opin Pharmacol. 2002 Oct;2(5):513-22. Review.

PMID:
12324252
35.

The Genomic Aspect of Virulence, Sepsis, and Resistance to Killing Mechanisms in Staphylococcus aureus.

Cheung AL, Projan SJ, Gresham H.

Curr Infect Dis Rep. 2002 Oct;4(5):400-410.

PMID:
12228026
37.

Genomics in anti-infective drug discovery--getting to endgame.

Haney SA, Alksne LE, Dunman PM, Murphy E, Projan SJ.

Curr Pharm Des. 2002;8(13):1099-118. Review.

PMID:
12052222
38.

Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reaction.

Ruzin A, Severin A, Ritacco F, Tabei K, Singh G, Bradford PA, Siegel MM, Projan SJ, Shlaes DM.

J Bacteriol. 2002 Apr;184(8):2141-7.

39.

Antibiotic resistance in bacteria from magpies (Pica pica) and rabbits (Oryctolagus cuniculus) from west Wales.

Livermore DM, Warner M, Hall LM, Enne VI, Projan SJ, Dunman PM, Wooster SL, Harrison G.

Environ Microbiol. 2001 Oct;3(10):658-61.

PMID:
11722546
40.

Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci.

Dunman PM, Murphy E, Haney S, Palacios D, Tucker-Kellogg G, Wu S, Brown EL, Zagursky RJ, Shlaes D, Projan SJ.

J Bacteriol. 2001 Dec;183(24):7341-53.

41.
42.

Bacterial virulence as a target for antimicrobial chemotherapy.

Alksne LE, Projan SJ.

Curr Opin Biotechnol. 2000 Dec;11(6):625-36. Review. Erratum in: Curr Opin Biotechnol 2001 Feb;12(1):112.

PMID:
11102800
43.

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

Projan SJ.

Pharmacotherapy. 2000 Sep;20(9 Pt 2):219S-223S; discussion 224S-228S.

PMID:
11001329
44.

Identification and analysis of bacterial protein secretion inhibitors utilizing a SecA-LacZ reporter fusion system.

Alksne LE, Burgio P, Hu W, Feld B, Singh MP, Tuckman M, Petersen PJ, Labthavikul P, McGlynn M, Barbieri L, McDonald L, Bradford P, Dushin RG, Rothstein D, Projan SJ.

Antimicrob Agents Chemother. 2000 Jun;44(6):1418-27.

45.
46.

Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae.

Ahmad M, Urban C, Mariano N, Bradford PA, Calcagni E, Projan SJ, Bush K, Rahal JJ.

Clin Infect Dis. 1999 Aug;29(2):352-5.

PMID:
10476741
47.

Recent developments in tetracycline antibiotics.

Sum PE, Sum FW, Projan SJ.

Curr Pharm Des. 1998 Apr;4(2):119-32. Review.

PMID:
10197036
48.
49.

Molecular epidemiology of Staphylococcus epidermidis blood isolates from neonatal intensive care unit patients.

Nesin M, Projan SJ, Kreiswirth B, Bolt Y, Novick RP.

J Hosp Infect. 1995 Oct;31(2):111-21.

PMID:
8551017
50.

The agr P2 operon: an autocatalytic sensory transduction system in Staphylococcus aureus.

Novick RP, Projan SJ, Kornblum J, Ross HF, Ji G, Kreiswirth B, Vandenesch F, Moghazeh S.

Mol Gen Genet. 1995 Aug 30;248(4):446-58.

PMID:
7565609

Supplemental Content

Loading ...
Support Center